Developer docs
API playgroundTry for free, no card

Search company profiles

Tolemy Bio

Full company profile

uuid00q7aip

Namestring
Tolemy Bio
Legal namestring
Tolemy Bio Ltd
Websiteurl
tolemy.bio
Company typeenum
Private
Founded yearint
2024
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI cell biology platform, cell therapy manufacturing, multi-omics optimization, virtual cell modeling, bioprocess development
Industry3 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Computational Biology Software
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Commercial partnerships / co-developed services (e.g., aiMOS™ with GeminiBio)
TypeProfessional Services
Description

Revenue appears to be generated through B2B commercial partnerships and co-developed services targeting cell therapy manufacturers. The aiMOS™ service is offered to customers to improve cell therapy performance, reduce costs, and support scaling — consistent with a managed-services or professional-services revenue motion alongside any underlying platform licensing.

businessweekly.co.uk
2Pre-revenue / partner-development phase
TypeSubscription Recurring
Description

Company is in active partner-acquisition mode ("We are looking for new partners and applications") suggesting revenue streams are not yet formalized; funding currently backs R&D rather than scaled monetization.

tolemy.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details1 tier
1Quote-based / Not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is not listed publicly; prospective customers are directed to "Get in Touch" via the platform CTA.

tolemy.bio
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Tolemy Bio builds an AI-native virtual cell platform that serves as an intelligence layer to direct cellular systems for better therapeutic outcomes. The platform helps teams map, simulate, and improve living systems across Cell Biology, Advanced Therapeutics, and Bioprocessing. It also powers the aiMOS™ service, co-developed with GeminiBio, which uses AI and multi-omics data to optimize cell culture media supplements for cell therapy manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Aims to improve cell therapy performance and reduce costs, and to support scaling from research to commercialization
+1 more record
Product overview1 text field

Tolemy Bio offers a single unified AI-native virtual cell platform (the "Tolemy Platform") that serves as the intelligence layer for therapeutic development and manufacture across Cell Biology, Advanced Therapeutics, and Bioprocessing. As a complement to this core platform, Tolemy Bio co-developed the aiMOS™ service with Gemini Bio, which leverages the platform's AI capabilities together with multi-omics data to optimize media supplements specifically for cell therapy manufacturing. Together, the Tolemy Platform provides the foundational virtual cell modeling and simulation capabilities, while aiMOS™ delivers an applied, co-branded offering targeting cell therapy media optimization within the broader bioprocessing and advanced therapeutics scope.

Product and service2 records
1Tolemy Platform
CategoryAI Bio-Platform
Description

The AI-native virtual cell platform for therapeutic development and manufacture. It serves as the intelligence layer to direct cellular systems for better therapeutic outcomes, spanning Cell Biology, Advanced Therapeutics, and Bioprocessing applications. Targeted at research and industry teams working on cell biology and bioprocessing.

2aiMOS™
CategoryCell Therapy Manufacturing Service
Description

A co-developed service with GeminiBio that leverages AI and multi-omics data to optimize media supplements for cell therapy manufacturing. Aims to improve cell therapy performance, reduce costs, and support scaling from research to commercialization. Targeted at cell therapy manufacturers and bioprocessing teams.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagship Commercial PartnershipTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

A collaboration between Tolemy Bio and California-based GeminiBio launched aiMOS™, a technology that leverages AI and multi-omics data to optimize media supplements for cell therapy manufacturing. The jointly offered service aims to improve cell therapy performance, reduce costs, and support scaling from research to commercialization.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Deepcell uses AI and microfluidics to characterize single cells at high throughput, comparable to Tolemy in combining AI with cell-level biological data. Its focus is single-cell analysis rather than cell therapy process optimization.

TypeDirect peer
Description

Insitro builds ML-driven models of human biology to accelerate drug discovery, a closely adjacent 'AI-native biology' play. Both companies pursue the same thesis that machine learning on biological data can transform therapeutic development.

TypeBroad incumbent
Description

Schrödinger applies physics-based computational modeling and ML to drug discovery and materials. Its physics-informed biology approach and AI-driven simulation tooling overlap conceptually with Tolemy's interdisciplinary software + physics + biology stack.

TypeEmerging player
Description

CytoReason builds AI models of the human cell for pharma R&D, using cell biology as its primary data domain. It is comparable to Tolemy in focusing on cell-level biological modeling, though its end-customers are pharma discovery teams rather than cell therapy manufacturers.

TypeBroad incumbent
Description

Recursion is a publicly listed AI-for-drug-discovery incumbent combining high-throughput biology with ML. It operates in the same AI-native biology category as Tolemy but at substantially greater scale and capital intensity.

6Culture Biosciences
TypeEmerging player
Description

Culture Biosciences operates a cloud bioprocess development platform, combining experimentation with data infrastructure for bioprocess R&D. It is comparable to Tolemy in addressing bioprocess scale-up and data-driven optimization for cell-based manufacturing.

TypeDirect peer
Description

Cradle applies AI/ML to biologics design and bioprocess optimization, directly overlapping with Tolemy's AI-for-biology and bioprocessing positioning. Both target the same bottleneck of using AI to design and optimize biological systems for therapeutic and industrial use.

TypeEmerging player
Description

Synthace offers a cloud-based platform for automating and optimizing biological experiments, directly overlapping with Tolemy's mission of providing an AI-driven interface to design and control wet-lab biology.

TypeEmerging player
Description

Owkin applies AI to biomedical and clinical data for drug discovery and development. It is thematically adjacent in the AI-for-biology category and competes for the same enterprise biopharma customer base.

TypeBroad incumbent
Description

Ginkgo is a publicly listed cell engineering and biosecurity platform. It competes in cell programming and bioprocess optimization — adjacent to Tolemy's cell biology and bioprocessing focus — and offers a much broader service portfolio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tolemy Bio

Computational Biology Softwaretolemy.bio

Tolemy Bio firmographics

Firmographics
Name
Tolemy Bio
Legal name
Tolemy Bio Ltd
Website
https://tolemy.bio
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Tolemy Bio industry classification

Industry
Product category
Computational Biology Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • AI cell biology platform
  • Cell therapy manufacturing
  • Multi-omics optimization
  • Virtual cell modeling
  • Bioprocess development

Where Tolemy Bio is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

Tolemy Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Commercial partnerships / co-developed services (e.g., aiMOS™ with GeminiBio): Revenue appears to be generated through B2B commercial partnerships and co-developed services targeting cell therapy manufacturers. The aiMOS™ service is offered to customers to improve cell therapy performance, reduce costs, and support scaling — consistent with a managed-services or professional-services revenue motion alongside any underlying platform licensing.
  2. Pre-revenue / partner-development phase: Company is in active partner-acquisition mode ("We are looking for new partners and applications") suggesting revenue streams are not yet formalized; funding currently backs R&D rather than scaled monetization.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based / Not publicly disclosed

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Tolemy Bio product offering

Product offering

Core offering

Tolemy Bio builds an AI-native virtual cell platform that serves as an intelligence layer to direct cellular systems for better therapeutic outcomes. The platform helps teams map, simulate, and improve living systems across Cell Biology, Advanced Therapeutics, and Bioprocessing. It also powers the aiMOS™ service, co-developed with GeminiBio, which uses AI and multi-omics data to optimize cell culture media supplements for cell therapy manufacturing.

Product overview

Tolemy Bio offers a single unified AI-native virtual cell platform (the "Tolemy Platform") that serves as the intelligence layer for therapeutic development and manufacture across Cell Biology, Advanced Therapeutics, and Bioprocessing. As a complement to this core platform, Tolemy Bio co-developed the aiMOS™ service with Gemini Bio, which leverages the platform's AI capabilities together with multi-omics data to optimize media supplements specifically for cell therapy manufacturing. Together, the Tolemy Platform provides the foundational virtual cell modeling and simulation capabilities, while aiMOS™ delivers an applied, co-branded offering targeting cell therapy media optimization within the broader bioprocessing and advanced therapeutics scope.

Differentiator

Problem solved

Functional benefit

Products and services

  • Tolemy Platform The AI-native virtual cell platform for therapeutic development and manufacture. It serves as the intelligence layer to direct cellular systems for better therapeutic outcomes, spanning Cell Biology, Advanced Therapeutics, and Bioprocessing applications. Targeted at research and industry teams working on cell biology and bioprocessing.
  • aiMOS™ A co-developed service with GeminiBio that leverages AI and multi-omics data to optimize media supplements for cell therapy manufacturing. Aims to improve cell therapy performance, reduce costs, and support scaling from research to commercialization. Targeted at cell therapy manufacturers and bioprocessing teams.

Quantifiable outcome

  • Aims to improve cell therapy performance and reduce costs, and to support scaling from research to commercialization
  • +1 more outcomes

Companies that use Tolemy Bio

Customer profile

Segments3 records

Ideal customer profiles3 records

Tolemy Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature2 records

Tolemy Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • GeminiBioflagship commercial partnershipStrategic or Co-development Partner · 11 February 2026A collaboration between Tolemy Bio and California-based GeminiBio launched aiMOS™, a technology that leverages AI and multi-omics data to optimize media supplements for cell therapy manufacturing. The jointly offered service aims to improve cell therapy performance, reduce costs, and support scaling from research to commercialization.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Tolemy Bio competitors and assessment

Company assessment

Emerging players

  • Deepcell: Deepcell uses AI and microfluidics to characterize single cells at high throughput, comparable to Tolemy in combining AI with cell-level biological data. Its focus is single-cell analysis rather than cell therapy process optimization.
  • CytoReason: CytoReason builds AI models of the human cell for pharma R&D, using cell biology as its primary data domain. It is comparable to Tolemy in focusing on cell-level biological modeling, though its end-customers are pharma discovery teams rather than cell therapy manufacturers.
  • Culture Biosciences: Culture Biosciences operates a cloud bioprocess development platform, combining experimentation with data infrastructure for bioprocess R&D. It is comparable to Tolemy in addressing bioprocess scale-up and data-driven optimization for cell-based manufacturing.
  • Synthace: Synthace offers a cloud-based platform for automating and optimizing biological experiments, directly overlapping with Tolemy's mission of providing an AI-driven interface to design and control wet-lab biology.
  • Owkin: Owkin applies AI to biomedical and clinical data for drug discovery and development. It is thematically adjacent in the AI-for-biology category and competes for the same enterprise biopharma customer base.

Direct peers

  • Insitro: Insitro builds ML-driven models of human biology to accelerate drug discovery, a closely adjacent 'AI-native biology' play. Both companies pursue the same thesis that machine learning on biological data can transform therapeutic development.
  • Cradle: Cradle applies AI/ML to biologics design and bioprocess optimization, directly overlapping with Tolemy's AI-for-biology and bioprocessing positioning. Both target the same bottleneck of using AI to design and optimize biological systems for therapeutic and industrial use.

Broad incumbents

  • Schrödinger: Schrödinger applies physics-based computational modeling and ML to drug discovery and materials. Its physics-informed biology approach and AI-driven simulation tooling overlap conceptually with Tolemy's interdisciplinary software + physics + biology stack.
  • Recursion Pharmaceuticals: Recursion is a publicly listed AI-for-drug-discovery incumbent combining high-throughput biology with ML. It operates in the same AI-native biology category as Tolemy but at substantially greater scale and capital intensity.
  • Ginkgo Bioworks: Ginkgo is a publicly listed cell engineering and biosecurity platform. It competes in cell programming and bioprocess optimization — adjacent to Tolemy's cell biology and bioprocessing focus — and offers a much broader service portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Tolemy Bio social profiles

Digital presence

Tolemy Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tolemy Bio leadership team

Management profile

Number of profiles

Profiles2 records

Tolemy Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tolemy Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tolemy Bio

What does Tolemy Bio do?

Tolemy Bio builds an AI-native virtual cell platform that serves as an intelligence layer to direct cellular systems for better therapeutic outcomes. The platform helps teams map, simulate, and improve living systems across Cell Biology, Advanced Therapeutics, and Bioprocessing. It also powers the aiMOS™ service, co-developed with GeminiBio, which uses AI and multi-omics data to optimize cell culture media supplements for cell therapy manufacturing.

Is Tolemy Bio a public or private company?

Tolemy Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Tolemy Bio founded?

Tolemy Bio was founded in 2024. It employs 1 to 10 people.

Where is Tolemy Bio based?

Tolemy Bio is headquartered in Barcelona, Spain, in the Europe region.

How does Tolemy Bio make money?

Two revenue lines are on record. Commercial partnerships / co-developed services (e.g., aiMOS™ with GeminiBio) is the primary driver. The others are pre-revenue / partner-development phase.

Who are Tolemy Bio's main competitors?

Emerging players on record are Deepcell, CytoReason, Culture Biosciences, Synthace and Owkin. Direct peers are Insitro and Cradle. Broad incumbents are Schrödinger, Recursion Pharmaceuticals and Ginkgo Bioworks.

Does Tolemy Bio have an API?

No public API is recorded for Tolemy Bio.

What industry is Tolemy Bio in?

Tolemy Bio's product category is Computational Biology Software. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
VestbeeTop European funding rounds closed in May 2026European startups closed funding rounds in May 2026, including Cytospire Therapeutics' £61M Series A and eleQtron's €57M Series A. The rounds span immuno-oncology, quantum computing, AI, and biotech, with capital used for clinical trials, scaling, and expansion.El ReferenteLa compañía barcelonesa Tolemy Bio ha recaudado 1,4 M€Tolemy Bio, a Barcelona-based biotech startup, raised €1.4 million in pre-seed funding led by Norrsken Evolve. The round, with participation from Big Sur Ventures and others, will support its AI-based cell control platform and team expansion. The company aims to make cell biology more predictable and scalable.El ReferenteLa compañía barcelonesa Tolemy Bio ha recaudado 1,4 M€Tolemy Bio, a Barcelona-based biotech startup, raised €1.4 million in pre-seed funding led by Norrsken Evolve with participation from Big Sur Ventures and others. The funds will support its AI-based cell control platform, Orbit, and help expand its Barcelona team and client base.El ReferenteLa compañía barcelonesa Tolemy Bio ha recaudado 1,4 M€Tolemy Bio, a Barcelona-based biotech startup, raised €1.4 million in pre-seed funding led by Norrsken Evolve. The round, with participation from Big Sur Ventures and others, will support its AI-based cell control platform and team expansion. The company aims to make cell biology more predictable and scalable.El ReferenteLa compañía barcelonesa Tolemy Bio ha recaudado 1,4 M€Tolemy Bio, a Barcelona-based company, raised €1.4 million in pre-seed funding led by Norrsken Evolve. The round, with participation from Big Sur Ventures and others, will support its AI-based cell control platform and team expansion. The company aims to make cell biology more predictable and scalable.Pulse 2.0Tolemy Bio Raises €1.4 Million Pre-Seed To Build AI-Native Platform For Understanding Cellular SystemsTolemy Bio raised €1.4 million in pre-seed funding led by Norrsken Evolve and Big Sur Ventures to develop Orbit, an AI-native platform for understanding cellular systems. The company will use the capital to scale Orbit, deepen customer relationships, and build its team.WebcapitalriesgoTolemy Bio cierra una ronda de €1,4M en la que participan Big Sur, Norrsken Evolve, JME, Masia y Redbus y Business angelsTolemy Bio closed a €1.4M pre-seed round with Big Sur, Norrsken Evolve, JME, Masia, Redbus, and business angels. The funds will accelerate its Orbit AI platform for cell biology, targeting cell therapy and biomanufacturing applications.VestbeeTolemy Bio secures €1.4M to build AI “Control Panel” for cell-based therapeuticsTolemy Bio raised €1.4 million in a pre-seed round led by Norrsken Evolve to develop Orbit, an AI platform for cell-based therapeutics. The company aims to integrate fragmented experimental data and improve reproducibility in research and manufacturing.Tech.euTolemy Bio lands €1.4M to power AI-driven cell biologyTolemy Bio raised €1.4 million in pre-seed funding led by Norrsken Evolve to advance its AI-enabled cell biology platform, Orbit. The system connects fragmented lab workflows and incorporates virtual cell models and AI research agents. The company will use the funds to expand data generation and machine learning capabilities.StartupmagTolemy Bio secures £1.2m seed to interpret and direct cells using AI modelsTolemy Bio closed a £1.21m seed round led by Big Sur Ventures to build Orbit, an AI-native platform for interpreting and directing cellular systems. The funding targets cell therapy and biomanufacturing, aiming to make experimental data actionable and reduce failed experiments. Proceeds will support product development, team expansion, and customer partnerships.